Carbon-nanoparticle-triggered acute lung inflammation and its resolution are not altered in PPARγ-defective (P465L) mice

Particle and Fibre Toxicology

Volumn 8, Issue , 2011, Pages

  Götz, Alexander A ^a   Vidal Puig, Antonio ^b   Rödel, Heiko G ^c   De Angelis, Martin H ^a   Stoeger, Tobias ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITÉ PARIS 13   (France)

Author keywords

Broncho alveolar lavage (bal); Carbon nano particle; Challenge; Chronic lung disease; Immune cell; Inflammatory marker; Peroxisome proliverator activated receptor ; Pulmonary inflammation

Indexed keywords

CARBON NANOPARTICLE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GALECTIN 3; LACTATE DEHYDROGENASE; NANOPARTICLE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY WALL; CELL DEATH; CELL LEVEL; CELL STIMULATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; EPITHELIUM CELL; FEMALE; GENETIC VARIABILITY; LIGAND BINDING; LUNG ALVEOLUS; LUNG LAVAGE; MACROPHAGE; MALE; MOLECULAR PATHOLOGY; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PNEUMONIA; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; SEX DIFFERENCE;

ACUTE LUNG INJURY; ANIMALS; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CARBON; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; LEUKOCYTES; MACROPHAGES, ALVEOLAR; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; NANOPARTICLES; POINT MUTATION; PPAR GAMMA; SEX FACTORS;

ANIMALIA; MURINAE; MUS;

EID: 80053175378     PISSN: None     EISSN: 17438977     Source Type: Journal    
DOI: 10.1186/1743-8977-8-28     Document Type: Article

References (52)

1. Kliewer S, Forman B, Blumberg B, Ong E, Borgmeyer U, Mangelsdorf D, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. PNAS 1994, 91:7355-7359. 10.1073/pnas.91.15.7355, 44398, 8041794.
2. Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. ANNU REV CELL DEV BI 1996, 12:335-363.
3. Simon D, Arikan M, Srisuma S, Bhattacharya S, Andalcio T, Shapiro S, Mariani TJ. Epithelial cell PPARgamma is an endogenous regulator of normal lung maturation and maintenance. POC AM THOR SOC 2006, 3:510-511.
4. Agarwal A, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J CLIN ENDOCR METAB 2002, 87:408-411. 10.1210/jc.87.1.408, 11788685.
5. Savage D, Tan G, Acerini C, Jebb S, Agostini M, Gurnell M, Williams R, Umpleby A, Thomas E, Bell J, et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. DIABETES 2003, 52:910-917. 10.2337/diabetes.52.4.910, 12663460.
6. Tsai Y, Kim H, Takahashi N, Kim H, Hagaman J, Kim J, Maeda N. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma. J CLIN INVEST 2004, 114:240-249. 449746, 15254591.
7. Gray S, Dall Nora E, Grosse J, Manieri M, Stoeger T, Medina-Gomez G, Burling K, Wattler S, Russ A, Yeo G, et al. Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice. DIABETES 2006, 55:2669-2677. 10.2337/db06-0389, 17003330.
8. Belvisi M, Mitchell J. Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. BRIT J PHARMACO 2009, 158:994-1003.
9. Becker J, Delayre-Orthez C, Frossard N, Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?. FUNDAM CLIN PHARM 2006, 20:429-447.
10. von Knethen A, Soller M, Brüne B. Peroxisome proliferator-activated receptor gamma (PPAR gamma) and sepsis. ARCH IMMUNOL THER EX 2007, 55:19-25.
11. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. DIABETES 1998, 47:507-514. 10.2337/diabetes.47.4.507, 9568680.
12. Reginato M, Krakow S, Bailey S, Lazar M. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J BIOL CHEM 1998, 273:1855-1858. 10.1074/jbc.273.4.1855, 9442016.
13. Lehmann J, Lenhard J, Oliver B, Ringold G, Kliewer S. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J BIOL CHEM 1997, 272:3406-3410. 10.1074/jbc.272.6.3406, 9013583.
14. Ricote M, Li A, Willson T, Kelly C, Glass C. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. NATURE 1998, 391:79-82. 10.1038/34178, 9422508.
15. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans R. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. NAT MED 2001, 7:48-52. 10.1038/83336, 11135615.
16. Szanto A, Nagy L. The many faces of PPARgamma: anti-inflammatory by any means?. IMMUNOBIOLOGY 2008, 213:789-803. 10.1016/j.imbio.2008.07.015, 18926294.
17. Yan C, Du H. Alveolus formation: what have we learned from genetic studies?. J APPL PHYSIOL 2004, 97:1543-1548. 10.1152/japplphysiol.00286.2004, 15358757.
18. Asada K, Sasaki S, Suda T, Chida K, Nakamura H. Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. AM J RESP CRIT CARE 2004, 169:195-200.
19. Reddy R, Keshamouni V, Jaigirdar S, Zeng X, Leff T, Thannickal V, Standiford TJ. Deactivation of murine alveolar macrophages by peroxisome proliferator-activated receptor-gamma ligands. Am J Physiol-Lung C 2004, 286:L613-L619.
20. Soehnlein O, Lindbom L. Phagocyte partnership during the onset and resolution of inflammation. NAT REV IMMUNOL 2010, 10:427-439. 10.1038/nri2779, 20498669.
21. Aronoff D, Serezani C, Carstens J, Marshall T, Gangireddy S, Peters-Golden M, Reddy RC. Stimulatory Effects of Peroxisome Proliferator-Activated Receptor-gamma on Fcgamma Receptor-Mediated Phagocytosis by Alveolar Macrophages. PPAR RES 2007, 2007. Hindawi Publishing Corporation.
22. Kintscher U, Wakino S, Bruemmer D, Goetze S, Graf K, Hsueh W, Law RE. TGF-beta(1) induces peroxisome proliferator-activated receptor gamma1 and gamma2 expression in human THP-1 monocytes. BIOCHEM BIOPH RES CO 2002, 297:794-799.
23. Momoi A, Murao K, Imachi H, Ishida T, Cao W, Sato M, Takahara J. Inhibition of monocyte chemoattractant protein-1 expression in cytokine-treated human lung epithelial cells by thiazolidinedione. CHEST 2001, 120:1293-1300. 10.1378/chest.120.4.1293, 11591574.
24. Wang A, Dai X, Luu B, Conrad DJ. Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. AM J RESP CELL MOL 2001, 24:688-693.
25. Hetzel M, Walcher D, Grub M, Bach H, Hombach V, Marx N. Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells. THORAX 2003, 58:778-783. 10.1136/thorax.58.9.778, 1746807, 12947137.
26. Culver D, Barna B, Raychaudhuri B, Bonfield T, Abraham S, Malur A, Farver C, Kavuru M, Thomassen M. Peroxisome proliferator-activated receptor gamma activity is deficient in alveolar macrophages in pulmonary sarcoidosis. AM J RESP CELL MOL 2004, 30:1-5.
27. Barna B, Culver D, Abraham S, Malur A, Bonfield T, John N, Farver C, Drazba J, Raychaudhuri B, Kavuru M, et al. Depressed peroxisome proliferator-activated receptor gamma (PPARgamma) is indicative of severe pulmonary sarcoidosis: possible involvement of interferon gamma (IFN-gamma). SARCOIDOSIS VASC DIF 2006, 23:93-100.
28. Smith M, Standiford T, Reddy R. PPARs in alveolar macrophage biology. PPAR RES 2007, 2007.
29. Belvisi M, Hele D, Birrell M. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. EUR J PHARMACOL 2006, 533:101-109. 10.1016/j.ejphar.2005.12.048, 16458290.
30. Lee S, Kang E, Hur G, Jung K, Jung H, Lee S, Kim J, Shin C, In K, Kang K, et al. Peroxisome proliferator-activated receptor-gamma inhibits cigarette smoke solution-induced mucin production in human airway epithelial (NCI-H292) cells. Am J Physiol-Lung C 2006, 291:L84-L90.
31. Genovese T, Cuzzocrea S, Di Paola R, Mazzon E, Mastruzzo C, Catalano P, Sortino M, Crimi N, Caputi A, Thiemermann C, et al. Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. EUR RESPIR J 2005, 25:225-234. 10.1183/09031936.05.00049704, 15684285.
32. Spears M, McSharry C, Thomson NC. Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. CLIN EXP ALLERGY 2006, 36:1494-1504. 10.1111/j.1365-2222.2006.02604.x, 17177672.
33. Milam J, Keshamouni V, Phan S, Hu B, Gangireddy S, Hogaboam C, Standiford T, Thannickal V, Reddy RC. PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol-Lung C 2008, 294:L891-L901.
34. Babaev V, Yancey P, Ryzhov S, Kon V, Breyer M, Magnuson M, Fazio S, Linton M. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. ARTERIOSCL THROM VAS 2005, 25:1647-1653.
35. Akiyama T, Sakai S, Lambert G, Nicol C, Matsusue K, Pimprale S, Lee Y, Ricote M, Glass C, Brewer HJ, et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. MOL CELL BIOL 2002, 22:2607-2619. 10.1128/MCB.22.8.2607-2619.2002, 133709, 11909955.
36. Chatterjee VK. Resistance to thyroid hormone, and peroxisome-proliferator-activated receptor gamma resistance. BIOCHEM SOC T 2001, 29:227-231.
37. Tan G, Savage D, Fielding B, Collins J, Hodson L, Humphreys S, O'Rahilly S, Chatterjee K, Frayn K, Karpe F. Fatty acid metabolism in patients with PPARgamma mutations. J CLIN ENDOCR METAB 2008, 93:4462-4470. 10.1210/jc.2007-2356, 18713822.
38. Boiani R, Cinti S, Savage D, Vidal-Puig A, O'Rahilly S. Abdominal subcutaneous adipose tissue morphology in a patient with a dominant-negative mutation (P467L) in the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPARG) gene. NUTR METAB CARDIOVAS 2010, 20:e11-12.
39. Kobayashi M, Thomassen M, Rambasek T, Bonfield T, Raychaudhuri B, Malur A, Winkler A, Barna B, Goldman S, Kavuru MS. An inverse relationship between peroxisome proliferator-activated receptor gamma and allergic airway inflammation in an allergen challenge model. ANN ALLERG ASTHMA IM 2005, 95:468-473.
40. Perez A, van Heeckeren A, Nichols D, Gupta S, Eastman J, Davis P. Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium. Am J Physiol-Lung C 2008, 295:303-313.
41. Stoeger T, Reinhard C, Takenaka S, Schroeppel A, Karg E, Ritter B, Heyder J, Schulz H. Instillation of six different ultrafine carbon particles indicates a surface area threshold dose for acute lung inflammation in mice. ENVIRON HEALTH PERSP 2006, 114:328-333.
42. Ganguly K, Upadhyay S, Irmler M, Takenaka S, Pukelsheim K, Beckers J, Hamelmann E, Schulz H, Stoeger T. Pathway focused protein profiling indicates differential function for IL-1B, -18 and VEGF during initiation and resolution of lung inflammation evoked by carbon nanoparticle exposure in mice. PART FIBRE TOXICOL 2009, 6.
43. Jacobsen N, Moller P, Jensen K, Vogel U, Ladefoged O, Loft S, Wallin H. Lung inflammation and genotoxicity following pulmonary exposure to nanoparticles in ApoE-/- mice. PART FIBRE TOXICOL 2009, 6.
44. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. SCIENCE 2006, 311:622-627. 10.1126/science.1114397, 16456071.
45. Duffin R, Mills N, Donaldson K. Nanoparticles-a thoracic toxicology perspective. YONSEI MED J 2007, 48.
46. Surazynski A, Jarzabek K, Miltyk W, Wolczynski S, Palka J. Estrogen-dependent regulation of PPAR-gamma signaling on collagen biosynthesis in adenocarcinoma endometrial cells. NEOPLASMA 2009, 56:448-454. 10.4149/neo_2009_05_448, 19580348.
47. Ueki S, Oguma M, Usami A, Kamada Y, Kato H, Kamada R, Takeda M, Ito W, Tanigai T, Kayaba H, et al. Regulation of peroxisome proliferator-activated receptor-gamma expression in human eosinophils by estradiol. INT ARCH ALLERGY IMM 2009, 149:51-56.
48. Andre E, Stoeger T, Takenaka S, Bahnweg M, Ritter B, Karg E, Lentner B, Reinhard C, Schulz H, Wjst M. Inhalation of ultrafine carbon particles triggers biphasic pro-inflammatory response in the mouse lung. EUR RESPIR J 2006, 28:275-285. 10.1183/09031936.06.00071205, 16641123.
49. Barroso I, Gurnell M, Crowley V, Agostini M, Schwabe J, Soos M, Maslen G, Williams T, Lewis H, Schafer A, et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999, 402:880-883.
50. Gray S, Dalla Nora E, Backlund E, Manieri M, Virtue S, Noland R, O'Rahilly S, Cortright R, Cinti S, Cannon B, et al. Decreased brown adipocyte recruitment and thermogenic capacity in mice with impaired peroxisome proliferator-activated receptor (P465L PPARgamma) function. ENDOCRINOLOGY 2006, 147:5708-5714. 10.1210/en.2006-0684, 16980437.
51. Brown R, Walters D, Greenberg R, Mitzner W. A method of endotracheal intubation and pulmonary functional assessment for repeated studies in mice. J APPL PHYSIOL 1999, 87:2362-2365.
52. Kodavanti U, Schladweiler MC, Schladweiler M, Ledbetter AD, AD L, Hauser R, Christiani D, McGee J, Richards J, Costa DL. Temporal association between pulmonary and systemic effects of particulate matter in healthy and cardiovascular compromised rats. J TOXICOL ENV HEAL A 2002, 65:1545-1569.